home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

11th Annual Proteins & Antibodies Congress

  August 23, 2017  
Oxford Global Conferences, London
16th - 17th April 2018

Oxford Global Conferences are proud to present our 11th Annual Proteins & Antibodies Congress, 16-17 April 2018, London, UK with our co-located 5th Annual Peptides Congress and 5th Annual Biosimilars & Biobetters Congress. Across the two days, over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions

Over 50 case studies, presentations and panel discussions focused on the key issues in protein and antibody engineering & development, protein & antibody biotherapeutics as well as biotherapeutics manufacturing and chemistry.

Including 5 interactive streams:

  • Protein Engineering, Design & Selection
  • Biotherapeutics: Manufacturing, Chemistry, Analytics and Control
  • Antibody Engineering, Design & Development
  • Cloning, Expressions, Purification & Analytics
  • Protein & Antibody Biotherapeutics

Download Agenda: http://bit.ly/2iqjUH3


Free Live Webinars

Protein & Antibody Biotherapeutics – Manufacturing & Developability Assessment
Hosted by
David Gervais, Head of Product Development, Porton Biopharma and Thorsten Lorenz, Group Head Developability Assessment 1, Novartis
Register for Free Today: http://bit.ly/2g4nJRl  

Antibody Biotherapeutics: Current Technologies And Recent Therapeutic Success
Hosted by David Mantus, Chief Development Officer,
Arsanis and Pallavi Tawde, Single B Cell Cloning Platform Leader, Bristol-Myers Squibb
Register for Free Today: http://bit.ly/2wnmDqw   

For further information regarding prices and possible discounts, please contact Danielle Dalby on d.dalby@oxfordglobal.co.uk or call +44 (0)1865 248 455.


Organized by: Oxford Global Conferences
Invited Speakers:

Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development
Merck & Co., Inc.

David Mantus, Chief Development Officer

Jens Frauenfeld, Chief Executive Officer
Salipro Biotech AB

Yanay Ofran, Chief Executive Officer & Founder and Professor of Biophysics and Computational Biology
Biolojic Design and Bar-Ilan University

Steffen Nock, Senior Vice President (Global Biologics Head)
Teva Pharmaceuticals

Syd Johnson, Vice President, Antibody Engineering

Annelise Vuidepot, Vice President, Head of Oncology Pipeline and Research

Sanjaya Singh, Vice President and Head, Biotherapeutics
Johnson & Johnson

Hari Hariharan, Senior Director, Biotherapeutics

Angela Norton, Senior Director and Head, Protein & Antibody Engineering
Shire Pharmaceuticals

Zhulun Wang, Executive Director, Research

Michelle Morrow, Director, Preclinical Translational Pharmacology
F-Star Biotechnology

Sujata Sharma, Director, Protein Science
Merck & Co., Inc.

Emma Harding, Director, Head of Molecular Design and Engineering

Ai Ching Lim, Director, Research

Andy Hooker, Director of Pharmaceutical Sciences
Ipsen Bioinnovation Ltd

Kenneth Walker, Director of Research, Biologics

Claire Dobson, Associate Director, Antibody Discovery and Protein Expression

Yung-Hsiang Kao, Associate Director and Principal Scientist

W. Blaine Stine, Associate Director, Discovery Biologics

Patrick Garidel, Associate Director, Protein Chemistry
Boehringer Ingelheim

Stefan Weigand, Global Head of Large Molecule Research
F.Hoffmann-La Roche

Katarina Radošević, Global Head Biologics Research
Sanofi R&D

Thorsten Lorenz, Group Head Developability Assessment 1

David Gervais, Head of Product Development
Porton Biopharma

Alexey Rak, Head, BioStructure & Biophysics

Darko Skegro, Senior Team Leader

Sharon McGonigle, Senior Principal Scientist

Michael Chin, Senior Principal Scientist and Associate Research Fellow

Tina Møller Tagmose, Principal Scientist
Novo Nordisk A/S

Jane Seagal, Principal Research Scientist

Sepideh Afshar, Principal Research Scientist, Department of Protein Engineering
Eli Lilly & Company

Sally Fischer, Principal Scientist and Group Leader

Carsten Behrens, Principal Scientist
Novo Nordisk A/S

Berthold Boedeker, Chief Scientist and Project Coordination
Bayer AG

Ren Liu, Team Leader and Associate Principal Scientist
Merck & Co., Inc.

Dorina Saro, Senior Research Scientist
Johnson & Johnson

Pallavi Tawde, Single B Cell Cloning Platform Leader
Bristol-Myers Squibb

Christopher Lloyds, Senior Scientist, Senior Scientist, Protein Engineering

Kaimeng Zhou, Analytical Team Lead
Bristol-Myers Squibb

Christian Bernloehr, Project Leader, Molecular Biology Department
Boehringer Ingelheim

Zhi Chen, Senior Scientist, Molecular and Analytical Development, Global Manufacturing & Supply
Bristol-Myers Squibb

Kerstin Otte, Professor
University of Applied Sciences Biberach

Jon Sayers, Professor of Functional Genomics
University of Sheffield

Alexander Golovanov, Senior Lecturer and Principal Investigator
Manchester Institute of Biotechnology and School of Chemistry, University of Manchester

Deadline for Abstracts: N/A

Register today: http://bit.ly/2xsqcZ6

E-mail: d.dalby@oxfordglobal.co.uk
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.